Medchemexpress LLC Zelebrudomide (NX-2127) | 2416131-46-7 | C39H45N9O5 | 50 MG

Supplier:  Medchemexpress LLC HY15322050MG

Zelebrudomide (NX-2127) is an orally active PROTAC degrader that targets Bruton's Tyrosine Kinase (Btk). It inhibits the proliferation of BTKC481S mutant TMD8 cells more effectively than Ibrutinib and appears as a light yellow to yellow solid. The compound has a molecular weight of 719.83.

• Targets Bruton's Tyrosine Kinase (Btk)
• Inhibits the proliferation of BTKC481S mutant TMD8 cells
• Catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3)
• Stimulates T cell activation
• Increases IL-2 production in primary human T cells
• Demonstrates potent degradation of BTK in cynomolgus monkeys in vivo
• Leads to superior tumor growth inhibition in both WT TMD8 and C481S mutant xenograft models in mice

Catalog No. 50-003-73511